Kyowa Kirin, Kura Oncology Launch Ziftomenib AML Trial
TOKYO & SAN DIEGO, April 24, 2026 Kyowa Kirin and Kura Oncology have announced a major clinical milestone with...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TOKYO & SAN DIEGO, April 24, 2026 Kyowa Kirin and Kura Oncology have announced a major clinical milestone with...
SAN DIEGO and PARIS, April 17, 2026 Kura Oncology, Inc. reported encouraging clinical data from its ongoing FIT-001 trial,...
SAN DIEGO and TOKYO, Oct. 1, 2025 — Kura Oncology and Kyowa Kirin have announced the first patient dosing...
